Highlights of This Issue 4171

SPECIAL FEATURES

CCR Translations

4173 CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer
Julie E. Bauman and Christine H. Chung
See related article, p. 4274

Statistics in Clinical Cancer Research

4176 Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven R. Alberts, Paul J. Catalano, and John Crowley

Molecular Pathways

4186 Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
Douglas B. Johnson, Keiran S.M. Smalley, and Jeffrey A. Sosman

4193 Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Shunsuke Okumura and Pasi A. Jänne

Perspectives

4200 Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

Review

4210 Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Channing J. Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia M. LoRusso, Laurence Baker, Larry Rubinstein, Erich Huang, Deborah Collyar, Susan Groszen, Steven Reeves, Lee M. Ellis, Daniel J. Sargent, Gary L. Rosner, Michael L. LeBlanc, and Mark J. Ratain

CANCER THERAPY: CLINICAL

4218 Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin, and Daniel J. George for the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation

4228 Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms’ Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Shigeo Koido, Sadamu Homma, Masato Okamoto, Kazuki Takakura, Masako Morii, Shinji Yoshizaki, Shintaro Tsukinaga, Shunichi Odifara, Seita Koyama, Hiroo Imazu, Kan Uchiyama, Mikio Kajihara, Hiroshi Arakawa, Takeyuki Misawa, Yoichi Toyama, Satoru Yanagisawa, Masahiro Ikegami, Shin Kan, Kazumi Hayashi, Hideo Komita, Yuko Kamata, Masaki Ito, Takefumi Ishidao, Sei-ichi Yusa, Shigetaka Shimodaara, Jianlin Gong, Haruo Sugiyama, Toshifumi Okhusa, and Hisao Tajiri

4240 Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Min Shi, Jiujie Cui, Jiawei Du, Daoyan Wei, Zhiliang Jia, Jun Zhang, Zhenggang Zhu, Yong Gao, and Keping Xie

Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid–Mediated Differentiation in Neuroblastoma
Nilay Shah, Jianjun Wang, Julia Selich-Anderson, Garrett Graham, Hasan Siddiqui, Xin Li, Javed Khan, and Jeffrey Toretsky

Correction: Interleukin-7 Mediates Selective Expansion of Tumor-Redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-Cell Inhibition

Correction: A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Correction: Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia

Integrative analysis of clear cell renal cell carcinoma shows predominant hypermethylation. A circos plot shows alterations in DNA methylation (hypermethylation in blue, outer ring), copy number variations (amplifications in red and deletions in green, middle ring), and expression (underexpressed in green, overexpressed in orange, innermost ring) in renal cell carcinoma when compared. For details, see the article by Hu and colleagues on page 4349 of this issue.